U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
MALVERN, Pa., April 25, 2017 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biopolymer-based drugs for the treatment of orphan diseases with an initial focus on cardiopulmonary disorders, today announced that Vice President of Research & Scientific Affairs Jim Ballance, Ph.D., will present preclinical and clinical data on the company’s proprietary elastin-like polypeptide (ELP) biopolymer technology platform in an oral session at the TIDES: Oligonucleotide & Peptide Therapeutics conference to be held April 30 - May 3 at the Manchester Grand Hyatt in San Diego, CA.
Details on the presentation are as follows:
Title: Elastin-Like Polypeptide Biopolymers Enhance the Pharmacology of Therapeutic Peptides
Track: Peptide Discovery, Preclinical and Clinical
Session: Peptides in the Clinic: Lessons Learned
Date / time: Tuesday, May 2, 3:05 - 3:30 p.m. PDT
Location: Cortez Hill
For additional information on the conference, please visit: https://lifesciences.knect365.com/tides/.
About PhaseBio
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company developing new and improved biotherapeutics for the treatment of orphan diseases, with a focus on cardiopulmonary disorders. The company’s proprietary technology platform uses recombinant elastin-like polypeptide (ELP) biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are engineered for a specific rate of absorption to enhance efficacy and reduce side effects, which can lead to less-frequent dosing and better patient compliance. PhaseBio's lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension (PAH); the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) and X-linked dilated cardiomyopathy; and the treatment of cystic fibrosis. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact: Laura Bagby, 6 Degrees (312) 448-8098 [email protected]
